Cirrhotomimetic hepatocellular carcinoma: experience of a single institution and review of the literature.

IF 1.2 Q4 ONCOLOGY Hepatic Oncology Pub Date : 2020-08-21 DOI:10.2217/hep-2020-0015

Meng-Jun Xiong, Chirag R Patel, Upender Manne, Sameer Al Diffalha

引用次数: 4

Abstract

Cirrhotomimetic hepatocellular carcinoma is a recognized pattern exhibiting cirrhosis-like growth and a reputation for evading pretransplant detection. Five cases encountered from our institution were retrospectively reviewed. Clinicopathologic and literature reviews were performed. All five patients were male, aged 50-66. Diffuse, innumerable nodules were seen grossly, exhibiting predominantly well-to-moderate differentiation with pseudoglandular and trabecular patterns microscopically. By immunohistochemistry, the tumor was diffusely positive for Glypican-3, showed sinusoidal capillarization by CD34 and slightly increased MIB-1 proliferation index. At up to 3.25 years of follow-up, our cohort of cirrhotomimetic hepatocellular carcinoma had no recurrence in 60% (3/5), solitary recurrence in 20% (1/5) and one patient had died of disease in 20% (1/5). Literature review suggests that these tumors recurred at a frequency of 50% (19 of 38 patients).

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

拟肝硬化肝细胞癌:单一机构的经验和文献回顾。

拟肝硬化肝细胞癌是一种公认的模式，表现为肝硬化样生长，并以逃避移植前检测而闻名。回顾性分析了我院收治的5例病例。进行临床病理和文献复习。5例患者均为男性，年龄50-66岁。弥漫性结节，肉眼可见无数结节，显微镜下主要表现为良好至中度分化，伴假腺和小梁型。免疫组化显示肿瘤Glypican-3弥漫性阳性，CD34呈窦状毛细血管化，mb -1增殖指数略有升高。在长达3.25年的随访中，我们的模拟肝硬化肝细胞癌队列中有60%(3/5)没有复发，20%(1/5)有单独复发，20%(1/5)有1例患者死于疾病。文献回顾表明，这些肿瘤复发的频率为50%(38例患者中有19例)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.